<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04254471</url>
  </required_header>
  <id_info>
    <org_study_id>AL3810-301</org_study_id>
    <nct_id>NCT04254471</nct_id>
  </id_info>
  <brief_title>This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients</brief_title>
  <official_title>Multicenter, Phase II/III Study of Carboplatin Plus Etoposide With AL3810 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ShangHai HaiHe Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ShangHai HaiHe Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II Study is to Evaluate the Safety and tolerability of AL3810 in combination with
      carboplatin plus (+) etoposide in untreated participants with ES-SCLC.

      Phase III Study is to Evaluate the efficacy of AL3810 in combination with carboplatin plus
      (+) etoposide in untreated participants with ES-SCLC.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 14, 2019</start_date>
  <completion_date type="Anticipated">November 22, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 22, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase II:adverse event(AE)/serious adverse event(SAE)</measure>
    <time_frame>From the date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months</time_frame>
    <description>AE/SAE to find the recommended dose of AL3810</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase III:1.PFS</measure>
    <time_frame>From the date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 56 months</time_frame>
    <description>1. Duration of Progression-Free Survival (PFS) as Assessed by the Independent Review Committee Using RECIST v1.1</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">313</enrollment>
  <condition>Extensive-stage Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Dose escalation (AL3810 + carboplatin + etoposide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase II:Participants will receive AL3810 orally in combination with carboplatin and etoposide during the Cycles 1-4 . AL3810 dose escalated form 5mg to 10mg step-up to determine the recommended dose of AL3810 in combination with carboplatin plus (+) etoposide in untreated participants with ES-SCLC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AL3810+ carboplatin + etoposide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase III:Participants will receive AL3810(recommended dose will be determined by safety monitoring committee (SMC) in Phase II) orally in combination with carboplatin and etoposide during the Cycles 1-4. Thereafter, participants will receive maintenance AL3810 until persistent radiographic PD, intolerable toxicity or withdrawal of consent, investigator's consideration, lost follow up, death ,study termination by the sponsor.whichever occurs first.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo+ carboplatin + etoposide</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Phase III:Participants will receive placebo orally in combination with carboplatin and etoposide during the induction Cycles 1-4. Thereafter, participants will receive maintenance placebo until persistent radiographic PD, intolerable toxicity or withdrawal of consent, investigator's consideration, lost follow up, death ,study termination by the sponsor.whichever occurs first.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AL3810</intervention_name>
    <description>5mgQD, 7.5mgQD, 10mgQD</description>
    <arm_group_label>AL3810+ carboplatin + etoposide</arm_group_label>
    <arm_group_label>Dose escalation (AL3810 + carboplatin + etoposide)</arm_group_label>
    <other_name>Lucitanib</other_name>
    <other_name>E3810</other_name>
    <other_name>E-3810</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin + etoposide</intervention_name>
    <description>Carboplatin and etoposide are background treatment.</description>
    <arm_group_label>AL3810+ carboplatin + etoposide</arm_group_label>
    <arm_group_label>Dose escalation (AL3810 + carboplatin + etoposide)</arm_group_label>
    <arm_group_label>Placebo+ carboplatin + etoposide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo+ carboplatin + etoposide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed Informed Consent Form

          -  Male or female, 18 ~75years of age

          -  Eastern Cooperative Oncology Group(ECOG) performance status of 0 or 1

          -  Histologically or cytologically confirmed ES-SCLC

          -  No prior treatment for ES-SCLC

          -  Measurable disease, as defined by RECIST v1.1

          -  Adequate hematologic and end organ function.

          -  Serum pregnancy test in screening period for women of childbearing potential should be
             negative.Except for women who have a history of sterilization or are
             postmenopausal.Men or woman subjects of reproductive age and their partners must agree
             to use effective contraception for at least 6 months from the date of signing the
             Informed Consent Form(ICF) until the last dose of the investigational therapy.

        exclusion criteria: main exclusion criteria

          -  Histologically confirmed mixed small cell lung cancer.

          -  Symptoms related to central nervous system(CNS) metastasis, unstable CNS metastasis,
             or CNS diseases needed the increase of steroid dosage to control.

          -  Uncontrolled hypertension.
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yixing Chen</last_name>
    <phone>+ 86-(021)-2056 8989</phone>
    <phone_ext>8903</phone_ext>
    <email>yixing.chen@haihepharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Chest Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baohui Han, M.D</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 16, 2020</study_first_submitted>
  <study_first_submitted_qc>February 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>February 3, 2020</last_update_submitted>
  <last_update_submitted_qc>February 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Rabeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

